As FDA regulations tighten, report says antimicrobial market headed for a crash

As the FDA continues its effort to phase out antimicrobials, the numbers aren't looking so good for the contracting market. A new report finds not only that growth in 2013 was sluggish, but predicts the North American marketshare will plummet 27%. The markets in Asia and Latin America, however, are forecasted to grow some 6% to 8%--a little bit of light at the end of the tunnel for those investing in emerging markets. The report finds that in 2013, animal health giants Zoetis ($ZTS), Elanco, Merck ($MRK), Merial and Bayer held about 75% of the entire antimicrobial market. More